Clinical Trial Update: Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea. [Phase 3]

View source ↗

Summary

This Phase 3 trial assesses the effects of biphasic insulin aspart 70/30 versus exenatide in adults with type 2 diabetes not reaching glycemic targets on metfor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Biphasic Insulin Aspart 70/30 (insulin aspart 70/30)
• EXENATIDE (EXENATIDE)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED